Which has better valuation & earnings, TECH or RGEN?

Bio-Techne has higher revenue and earnings than Repligen. Bio-Techne is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Techne $1.22B 9.36 $181.86M $1.15 63.07 Repligen $738.26M 12.78 $48.89M $0.73 229.07

Is TECH or RGEN more profitable?

Bio-Techne has a net margin of 14.97% compared to Repligen's net margin of 5.29%. Bio-Techne's return on equity of 13.23% beat Repligen's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Techne 14.97% 13.23% 10.61% Repligen 5.29% 5.30% 3.79%

Does the media refer more to TECH or RGEN?

In the previous week, Repligen had 3 more articles in the media than Bio-Techne. MarketBeat recorded 7 mentions for Repligen and 4 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 0.81 beat Repligen's score of 0.55 indicating that Bio-Techne is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TECH or A?

In the previous week, Agilent Technologies had 4 more articles in the media than Bio-Techne. MarketBeat recorded 8 mentions for Agilent Technologies and 4 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 0.81 beat Agilent Technologies' score of 0.05 indicating that Bio-Techne is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agilent Technologies 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BIO or TECH?

In the previous week, Bio-Rad Laboratories and Bio-Rad Laboratories both had 4 articles in the media. Bio-Techne's average media sentiment score of 0.81 beat Bio-Rad Laboratories' score of 0.48 indicating that Bio-Techne is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Rad Laboratories 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bio-Techne 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TECH or CRL?

In the previous week, Charles River Laboratories International had 22 more articles in the media than Bio-Techne. MarketBeat recorded 26 mentions for Charles River Laboratories International and 4 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 0.81 beat Charles River Laboratories International's score of 0.73 indicating that Bio-Techne is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Charles River Laboratories International 4 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, TECH or DHR?

Danaher has higher revenue and earnings than Bio-Techne. Danaher is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Techne $1.22B 9.36 $181.86M $1.15 63.07 Danaher $24.57B 6.26 $3.61B $5.63 38.87

Is TECH or DHR more profitable?

Danaher has a net margin of 15.95% compared to Bio-Techne's net margin of 14.97%. Bio-Techne's return on equity of 13.23% beat Danaher's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Techne 14.97% 13.23% 10.61% Danaher 15.95% 11.04% 6.81%

Does the media favor TECH or DHR?

In the previous week, Danaher had 30 more articles in the media than Bio-Techne. MarketBeat recorded 34 mentions for Danaher and 4 mentions for Bio-Techne. Danaher's average media sentiment score of 1.10 beat Bio-Techne's score of 0.81 indicating that Danaher is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Danaher 22 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Bio-Techne (TECH) Competitors

$72.53 +0.10 (+0.14%)

Closing price 10/7/2026 04:00 PM Eastern

Extended Trading

$72.52 -0.02 (-0.02%)

As of 07:40 AM Eastern

Compare

TECH vs. RGEN, A, BIO, CRL, and DHR

Should you buy Bio-Techne stock or one of its competitors? Bio-Techne's main competitors and comparable companies include Repligen (RGEN), Agilent Technologies (A), Bio-Rad Laboratories (BIO), Charles River Laboratories International (CRL), and Danaher (DHR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Bio-Techne compare to Repligen?

Bio-Techne (NASDAQ:TECH) and Repligen (NASDAQ:RGEN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

In the previous week, Repligen had 3 more articles in the media than Bio-Techne. MarketBeat recorded 7 mentions for Repligen and 4 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 0.81 beat Repligen's score of 0.55 indicating that Bio-Techne is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bio-Techne presently has a consensus price target of $68.92, indicating a potential downside of 4.97%. Repligen has a consensus price target of $173.21, indicating a potential upside of 3.58%. Given Repligen's stronger consensus rating and higher possible upside, analysts plainly believe Repligen is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	0 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.12
Repligen	0 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.89

Bio-Techne has higher revenue and earnings than Repligen. Bio-Techne is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.36	$181.86M	$1.15	63.07
Repligen	$738.26M	12.78	$48.89M	$0.73	229.07

Bio-Techne has a net margin of 14.97% compared to Repligen's net margin of 5.29%. Bio-Techne's return on equity of 13.23% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	14.97%	13.23%	10.61%
Repligen	5.29%	5.30%	3.79%

99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by company insiders. Comparatively, 0.6% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Bio-Techne has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, Repligen has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

Summary

Bio-Techne beats Repligen on 10 of the 17 factors compared between the two stocks.

How does Bio-Techne compare to Agilent Technologies?

Bio-Techne (NASDAQ:TECH) and Agilent Technologies (NYSE:A) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Agilent Technologies had 4 more articles in the media than Bio-Techne. MarketBeat recorded 8 mentions for Agilent Technologies and 4 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 0.81 beat Agilent Technologies' score of 0.05 indicating that Bio-Techne is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agilent Technologies	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Agilent Technologies has higher revenue and earnings than Bio-Techne. Agilent Technologies is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.36	$181.86M	$1.15	63.07
Agilent Technologies	$6.95B	6.86	$1.30B	$5.08	33.28

Bio-Techne has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market.

Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.4%. Agilent Technologies pays an annual dividend of $1.02 per share and has a dividend yield of 0.6%. Bio-Techne pays out 27.8% of its earnings in the form of a dividend. Agilent Technologies pays out 20.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Agilent Technologies has raised its dividend for 9 consecutive years. Agilent Technologies is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Agilent Technologies has a net margin of 19.53% compared to Bio-Techne's net margin of 14.97%. Agilent Technologies' return on equity of 24.45% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	14.97%	13.23%	10.61%
Agilent Technologies	19.53%	24.45%	13.09%

Bio-Techne presently has a consensus price target of $68.92, suggesting a potential downside of 4.97%. Agilent Technologies has a consensus price target of $171.82, suggesting a potential upside of 1.63%. Given Agilent Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Agilent Technologies is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	0 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.12
Agilent Technologies	0 Sell rating(s)	5 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.74

99.0% of Bio-Techne shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Agilent Technologies beats Bio-Techne on 13 of the 19 factors compared between the two stocks.

How does Bio-Techne compare to Bio-Rad Laboratories?

Bio-Rad Laboratories (NYSE:BIO) and Bio-Techne (NASDAQ:TECH) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

65.2% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 99.0% of Bio-Techne shares are held by institutional investors. 30.3% of Bio-Rad Laboratories shares are held by company insiders. Comparatively, 1.3% of Bio-Techne shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Bio-Rad Laboratories presently has a consensus target price of $343.33, indicating a potential downside of 6.75%. Bio-Techne has a consensus target price of $68.92, indicating a potential downside of 4.97%. Given Bio-Techne's higher probable upside, analysts plainly believe Bio-Techne is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20
Bio-Techne	0 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.12

Bio-Rad Laboratories has higher revenue and earnings than Bio-Techne. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58B	3.81	$759.90M	$8.25	44.63
Bio-Techne	$1.22B	9.36	$181.86M	$1.15	63.07

Bio-Techne has a net margin of 14.97% compared to Bio-Rad Laboratories' net margin of 8.59%. Bio-Techne's return on equity of 13.23% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	8.59%	3.54%	2.48%
Bio-Techne	14.97%	13.23%	10.61%

Bio-Rad Laboratories has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market.

In the previous week, Bio-Rad Laboratories and Bio-Rad Laboratories both had 4 articles in the media. Bio-Techne's average media sentiment score of 0.81 beat Bio-Rad Laboratories' score of 0.48 indicating that Bio-Techne is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Rad Laboratories	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bio-Techne	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bio-Techne beats Bio-Rad Laboratories on 10 of the 15 factors compared between the two stocks.

How does Bio-Techne compare to Charles River Laboratories International?

Bio-Techne (NASDAQ:TECH) and Charles River Laboratories International (NYSE:CRL) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Bio-Techne has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

Bio-Techne presently has a consensus price target of $68.92, indicating a potential downside of 4.97%. Charles River Laboratories International has a consensus price target of $300.11, indicating a potential downside of 0.03%. Given Charles River Laboratories International's stronger consensus rating and higher probable upside, analysts clearly believe Charles River Laboratories International is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	0 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.12
Charles River Laboratories International	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.88

In the previous week, Charles River Laboratories International had 22 more articles in the media than Bio-Techne. MarketBeat recorded 26 mentions for Charles River Laboratories International and 4 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 0.81 beat Charles River Laboratories International's score of 0.73 indicating that Bio-Techne is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Charles River Laboratories International	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bio-Techne has higher earnings, but lower revenue than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.36	$181.86M	$1.15	63.07
Charles River Laboratories International	$4.02B	3.57	-$144.34M	-$4.85	N/A

Bio-Techne has a net margin of 14.97% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	14.97%	13.23%	10.61%
Charles River Laboratories International	-5.96%	15.75%	6.51%

99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Bio-Techne and Charles River Laboratories International tied by winning 8 of the 16 factors compared between the two stocks.

How does Bio-Techne compare to Danaher?

Bio-Techne (NASDAQ:TECH) and Danaher (NYSE:DHR) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

Bio-Techne presently has a consensus target price of $68.92, suggesting a potential downside of 4.97%. Danaher has a consensus target price of $235.23, suggesting a potential upside of 7.48%. Given Danaher's stronger consensus rating and higher possible upside, analysts plainly believe Danaher is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	0 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.12
Danaher	0 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91

Danaher has a net margin of 15.95% compared to Bio-Techne's net margin of 14.97%. Bio-Techne's return on equity of 13.23% beat Danaher's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	14.97%	13.23%	10.61%
Danaher	15.95%	11.04%	6.81%

99.0% of Bio-Techne shares are held by institutional investors. Comparatively, 79.1% of Danaher shares are held by institutional investors. 1.3% of Bio-Techne shares are held by insiders. Comparatively, 10.8% of Danaher shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.4%. Danaher pays an annual dividend of $1.60 per share and has a dividend yield of 0.7%. Bio-Techne pays out 27.8% of its earnings in the form of a dividend. Danaher pays out 28.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Danaher has raised its dividend for 2 consecutive years. Danaher is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Danaher had 30 more articles in the media than Bio-Techne. MarketBeat recorded 34 mentions for Danaher and 4 mentions for Bio-Techne. Danaher's average media sentiment score of 1.10 beat Bio-Techne's score of 0.81 indicating that Danaher is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Danaher	22 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Danaher has higher revenue and earnings than Bio-Techne. Danaher is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.36	$181.86M	$1.15	63.07
Danaher	$24.57B	6.26	$3.61B	$5.63	38.87

Bio-Techne has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, Danaher has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

Summary

Danaher beats Bio-Techne on 13 of the 20 factors compared between the two stocks.

Get Bio-Techne News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TECH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TECH vs. The Competition

Export

Metric	Bio-Techne	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.36B	$10.53B	$7.16B	$13.44B
Dividend Yield	0.44%	1.44%	2.53%	16.47%
P/E Ratio	63.07	32.02	274.55	26.10
Price / Sales	9.36	106.32	571.53	87.31
Price / Cash	30.85	27.56	77.41	52.81
Price / Book	5.38	6.71	10.79	6.27
Net Income	$181.86M	$56.67B	$3.50B	$382.03M
7 Day Performance	0.18%	-0.25%	-0.39%	-0.52%
1 Month Performance	0.30%	7.61%	-6.11%	-4.80%
1 Year Performance	19.77%	28.79%	4.15%	-0.71%

Bio-Techne Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TECH Bio-Techne	2.8703 of 5 stars	$72.53 +0.1%	$68.92 -5.0%	+22.5%	$11.36B	$1.22B	63.07	3,000
RGEN Repligen	2.6719 of 5 stars	$194.09 +2.3%	$168.57 -13.1%	+14.6%	$10.70B	$738.26M	265.88	2,000	Analyst Forecast
A Agilent Technologies	4.1728 of 5 stars	$175.42 +1.5%	$170.33 -2.9%	+22.0%	$48.71B	$6.95B	34.53	18,100	Analyst Forecast
BIO Bio-Rad Laboratories	1.9284 of 5 stars	$377.75 -0.9%	$343.33 -9.1%	+24.2%	$10.19B	$2.58B	45.79	7,450
CRL Charles River Laboratories International	3.3533 of 5 stars	$294.85 +0.7%	$290.00 -1.6%	+76.5%	$13.98B	$4.02B	N/A	19,700	Trending News Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TECH) was last updated on 10/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Techne (TECH) Competitors

TECH vs. RGEN, A, BIO, CRL, and DHR

How does Bio-Techne compare to Repligen?

Summary

How does Bio-Techne compare to Agilent Technologies?

Summary

How does Bio-Techne compare to Bio-Rad Laboratories?

Summary

How does Bio-Techne compare to Charles River Laboratories International?

Summary

How does Bio-Techne compare to Danaher?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECH vs. The Competition

Bio-Techne Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bio-Techne (TECH) Competitors

TECH vs. RGEN, A, BIO, CRL, and DHR

How does Bio-Techne compare to Repligen?

Does the media refer more to TECH or RGEN?

Do analysts prefer TECH or RGEN?

Which has better valuation & earnings, TECH or RGEN?

Is TECH or RGEN more profitable?

Do insiders & institutionals believe in TECH or RGEN?

Which has more risk and volatility, TECH or RGEN?

Summary

How does Bio-Techne compare to Agilent Technologies?

Does the media favor TECH or A?

Which has preferable earnings & valuation, TECH or A?

Which has more risk and volatility, TECH or A?

Is TECH or A a better dividend stock?

Is TECH or A more profitable?

Do analysts prefer TECH or A?

Do insiders and institutionals have more ownership in TECH or A?

Summary

How does Bio-Techne compare to Bio-Rad Laboratories?

Do insiders & institutionals believe in BIO or TECH?

Do analysts rate BIO or TECH?

Which has preferable valuation and earnings, BIO or TECH?

Is BIO or TECH more profitable?

Which has more volatility & risk, BIO or TECH?

Does the media prefer BIO or TECH?

Summary

How does Bio-Techne compare to Charles River Laboratories International?

Which has more volatility and risk, TECH or CRL?

Do analysts prefer TECH or CRL?

Does the media refer more to TECH or CRL?

Which has preferable valuation & earnings, TECH or CRL?

Is TECH or CRL more profitable?

Do insiders & institutionals have more ownership in TECH or CRL?

Summary

How does Bio-Techne compare to Danaher?

Do analysts prefer TECH or DHR?

Is TECH or DHR more profitable?

Do insiders and institutionals hold more shares of TECH or DHR?

Is TECH or DHR a better dividend stock?

Does the media favor TECH or DHR?

Which has better earnings and valuation, TECH or DHR?

Which has more risk & volatility, TECH or DHR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECH vs. The Competition

Bio-Techne Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools